A kind of fluorescent molecular probe targeting EGFR and its preparation method and application

Abstract

The invention relates to the technical field of molecular probes, and discloses a fluorescent molecular probe targeting EGFR and its preparation method and application. The fluorescent molecular probe includes a fluorescent labeling group, a linking group and a reactive group; the reactive group The group can be targetedly combined with the EGFR protein, and can be specifically labeled, traced, and imaged through the fluorescent labeling group; the expression process of specific cells and molecules can be observed in real time by using molecular imaging, and the target site can be detected. Tracking, so as to realize the evaluation of disease development at the molecular pathological level and the precise detection of EGFR mutation typing in lung cancer patients.

Description

technical field [0001] The invention belongs to the technical field of molecular probes, in particular to a fluorescent molecular probe targeting EGFR and its preparation method and application. Background technique [0002] In recent years, molecular targeted drugs have been widely used, which is one of the major breakthroughs in clinical tumor treatment. For example, gefitinib (Iressa) and erlotinib (Tarceva) are two targeted drugs for the treatment of non-small cell lung cancer, which belong to the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI ). Accurate detection of EGFR mutation typing in lung cancer is the key to the use of molecular targeted drugs in the treatment of lung cancer. [0003] Clinically, before using TKI-targeted drugs in patients with non-small cell lung cancer, it is necessary to detect the EGFR gene mutation status. However, it is difficult to achieve accurate detection of EGFR mutation typing in lung cancer patients with exi...

AI Technical Summary

Problems solved by technology

[0005] 2) Secondly, the existing EGFR mutation detection methods all have certain limitations. For example, the use of molecular pathology to detect EGFR mutations has poor reproducibility and cannot overcome spatial heterogeneity. Relatively speaking, molecular detection is more convenient and reproducible , but the disadvantage is that the mutation status of the primary tumor cannot be obtained directly, and the problem of heterogeneity within the primary tumor and metastases of lung cancer cannot be solved

[0006] In addition, traditional imaging methods such as CT and MRI cannot reflect the information of EGFR molecular typing at the molecular level.

Images